¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚvic3308 ¤™
-
¿Æ¼¼Á¢Òì ¤™
-
²úÆ·ÓëÓªÒµ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°ÒµÉú³¤ ¤™
¼ò
¤™
- ÂýÐÔÉöÔಡ£¡£¡£¡£¡£¡£¨CKD£©ÊÇÎÒ¹ú³£¼ûµÄÂýÐÔ¼²²¡Ö®Ò»£¬£¬£¬£¬ £¬¶øÓÉÆäÒýÆðµÄ²¢·¢Ö¢¡ª¡ªÉöÐÔѪÐ飬£¬£¬£¬ £¬¸üÊÇÑÏÖØÓ°Ï컼ÕßÉúÑÄÖÊÁ¿Óëºã¾Ã¿µ½¡×´Ì¬[1]¡£¡£¡£¡£¡£¡£
- ÔÚ¸ÄÉÆÈ«ÇòÉöÔಡԤºó×éÖ¯£¨KDIGO£©¿ËÈÕÕýʽÐû²¼µÄ2026 °æ¡¶KDIGO ÂýÐÔÉöÔಡѪÐéÖÎÀíÁÙ´²Êµ¼ùÖ¸ÄÏ¡·ÖУ¬£¬£¬£¬ £¬ÈÔÍƼöºìϸ°ûÌìÉú´Ì¼¤¼Á£¨ESAs£©¶ø·ÇȱÑõÓÕµ¼Òò×Ó-¸¬°±õ£ôÇ»¯Ã¸ÒÖÖƼÁ£¨HIF-PHIs£©×÷ΪÉöÐÔѪÐ黼ÕßµÄÒ»ÏßÖÎÁƼƻ®[2]¡£¡£¡£¡£¡£¡£
- Óë³£¼ûµÄ¡°´ÙºìËØ¡±Õë¼Á²î±ð£¬£¬£¬£¬ £¬Óɺ²ÉÖÆÒ©×ÔÖ÷Ñз¢µÄÁ¢ÒìÒ©ÅàĪɳëÄ×¢ÉäÒº£¨ÉÌÆ·Ãû£ºÊ¥ÂÞÀ³?£©ÊÇÒ»ÖÖ³¤Ð§ESAs£¬£¬£¬£¬ £¬Ò²ÊÇÏÖÔÚÉöÐÔѪÐéÁìÓòÈ«ÇòΨһÉÏÊеÄС·Ö×ÓëÄÀ໯ѧҩÎ£¬£¬£¬ £¬ÇÒÿÔ½öÐèƤÏÂ×¢ÉäÒ»´Î[3]£¬£¬£¬£¬ £¬¼´¿É³¤Ð§¡¢Æ½ÎȵØÌáÉýѪºìÂÑ°×ˮƽ¡£¡£¡£¡£¡£¡£
¹Å°åµÄÖØ×éÈË´Ùºìϸ°ûÌìÉúËØ£¨rHuEPO£©ÊÇͨ¹ý»ùÒò¹¤³ÌºÏ³ÉµÄÉúÎïÖƼÁ£¬£¬£¬£¬ £¬Æä½á¹¹ÓëÈËÌåÄÚ×ÔÈ»±£´æµÄ´Ùºìϸ°ûÌìÉúËØ£¨EPO£©¸ß¶ÈÀàËÆ[1]¡£¡£¡£¡£¡£¡£¶øÅàĪɳëĵĽµÉúÔòµÃÒæÓÚÒ»Ïîŵ±´¶û½±»ñ½±ÊÖÒÕ¡ª¡ªÊɾúÌåչʾÊÖÒÕ£¨phage display£©[9]¡£¡£¡£¡£¡£¡£¿£¿£¿£¿ £¿£¿ÆÑÐְԱͨ¹ý¸ÃÊÖÒÕ£¬£¬£¬£¬ £¬´ÓÊɾúÌåչʾëÄ¿âÖÐɸѡ³öÄÜÓëÈËÌåEPOÊÜÌåϸÃÜÍŽáµÄС·Ö×ÓëÄ£¬£¬£¬£¬ £¬ÔÙ¾ÓɾÛÒÒ¶þ´¼£¨PEG£©ÐÞÊΣ¬£¬£¬£¬ £¬×îÖÕÐγÉÁËȫнṹµÄÅàĪɳëÄ¡£¡£¡£¡£¡£¡£
ÓÉÓÚÆä°±»ùËáÐòÁÐÓëÈËÌåÄÚÔ´ÐÔEPOÍêÈ«²î±ð£¬£¬£¬£¬ £¬Òò´Ë¿ÉÒÔ×èÖ¹½»Ö¯ÃâÒß·´Ó¦£¬£¬£¬£¬ £¬½µµÍÒòʹÓÃÍâÔ´ÐÔEPO¿ÉÄܵ¼Öµġ°´¿ºìϸ°ûÔÙÉúÕÏ°ÐÔѪÐ飨PRCA£©¡±Î£º¦[5]¡£¡£¡£¡£¡£¡£
¶ÌЧrHuEPOͨ³£ÐèÒª¾ÙÐÐƵÈÔ×¢É䣬£¬£¬£¬ £¬¸ø»¼Õß´øÀ´Î´±ã£¬£¬£¬£¬ £¬µ¹ÔËÓÚÉöÐÔѪÐéµÄºã¾ÃÖÎÀí¡£¡£¡£¡£¡£¡£ÅàĪɳëĽÓÄÉÈý´ú·ÖÖ§ÐÍPEGÐÞÊÎÊÖÒÕ£¬£¬£¬£¬ £¬Äܹ»ÓÐÓÃÑÓÉì°ëË¥ÆÚÖÁ70Сʱ×óÓÒ[3]£¬£¬£¬£¬ £¬´Ó¶øÑÓÉì¸øÒ©¾àÀë¡£¡£¡£¡£¡£¡£
È»¶ø£¬£¬£¬£¬ £¬ÅàĪɳëĵij¤Ð§×÷Óò¢²»µ«½öÊÇÓÉÓÚ°ëË¥ÆÚÑÓÉì¡£¡£¡£¡£¡£¡£ÓÐÑо¿ÏÔʾ£¬£¬£¬£¬ £¬ÓërHuEPOºÍ´ïÒÀ²´Í¡¦ÁÏà±È£¬£¬£¬£¬ £¬ÅàĪɳëÄÄܹ»Óë¾ßÓдٺì×÷ÓõÄEPOÊÜÌåÐγɸ߶ÈÎȹÌÇÒ³¤ÆÚµÄÍŽᣬ£¬£¬£¬ £¬ÆäÔÚEPOÊÜÌåÉϵÄÖÍÁôʱ¼äԼΪrHuEPOµÄ6.4¡«6.8±¶£¬£¬£¬£¬ £¬²¢¿Éͨ¹ýά³Öϸ°ûÍâòEPOÊÜÌåµÄ±í´ï£¬£¬£¬£¬ £¬Î¬³ÖÏÂÓÎÐźÅͨ·һÁ¬¼¤»îÒÔÌìÉúºìϸ°û¡£¡£¡£¡£¡£¡£¶¯ÎïʵÑéºÍÁ½ÏîIIÆÚÁÙ´²ÊÔÑéҲ֤ʵÁËÅàĪɳëľßÓÐÒ©´ú¶¯Á¦Ñ§£¨PK£©ºÍҩЧѧ£¨PD£©Ë«ÑÓÉìЧӦ£¬£¬£¬£¬ £¬ÇÒÄÍÊÜÐÔÓÅÒì[10]£¬£¬£¬£¬ £¬´Ó¶øΪÅàĪɳëĵij¤Ð§´Ùºìϸ°ûÌìÉú×÷ÓÃÌṩÁËÀíÂÛÒÀ¾Ý¡£¡£¡£¡£¡£¡£
2025ÄêÐû²¼µÄ¡¶Ö¸µ¼ÉöÐÔѪÐ黼Õß×ÔÎÒÖÎÀíµÄÖйúר¼Ò¹²Ê¶¡·Ã÷È·Ö¸³ö£¬£¬£¬£¬ £¬Ê¹ÓðëË¥ÆÚ³¤µÄÒ©ÎÈçÅàĪɳëĵȳ¤Ð§ÖƼÁ£©¿ÉïÔÌ×¢Éä´ÎÊý¡¢Ìá¸ßÖÎÁÆÒÀ´ÓÐÔ[6]¡£¡£¡£¡£¡£¡£
͸ÎöÈËȺÖÐÁÆЧµÖ´ï·ÇÁÓЧÐÔÖյ㣬£¬£¬£¬ £¬ÉõÖÁÕ¹ÏÖ³ö¸üÓÅÇ÷ÊÆ
¡¶ÁøÒ¶µ¶¡·×Ó¿¯EClinicalMedicine½ÒÏþµÄÒ»ÏîÕë¶Ô¶ÌЧrHuEPO¾ÖεÄ͸ÎöѪÐ黼ÕßµÄËæ»ú¡¢¿ª·ÅÐÔ¡¢ÑôÐÔ±ÈÕÕ¡¢·ÇÁÓЧÐÔ¢óÆÚÊÔÑéÑо¿£¬£¬£¬£¬ £¬ÄÉÈëÀ´×ÔÖйúµÄ43¼ÒÑо¿ÖÐÐĹ²372Àý»¼Õߣ¬£¬£¬£¬ £¬Ëæ»ú2£º1·ÖÅÉÖÁÅàĪɳëÄ×é»ò¶ÌЧrHuEPO×é¡£¡£¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬ £¬ÅàĪɳëÄ×éѪºìÂÑ°×£¨Hb£©Ë®Æ½´Ó»ùÏßÖÁÁÆЧÆÀ¹ÀÆÚµÄƽ¾ùת±äΪ0.07£¨0.92£©g/dL£¬£¬£¬£¬ £¬rHuEPO×éΪ-0.22£¨0.97£©g/dL£¬£¬£¬£¬ £¬×é¼ä²î±ðΪ0.29 g/dL£¨95%CI£º0.11¡«0.47£©¡£¡£¡£¡£¡£¡£Åú×¢ÅàĪɳëÄÔÚÖ÷ÒªÁÆЧÖյ㷽Ãæ·ÇÁÓЧÓÚrHuEPO¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬ £¬ÖÃÐÅÏÞÏÂÏÞ£¨0.11£©¸ßÓÚÁ㣬£¬£¬£¬ £¬Åú×¢ÅàĪɳëÄÔÚÁÆЧÉϾßÓиüÓŵÄÇ÷ÊÆ[11]¡£¡£¡£¡£¡£¡£
ÃÀ¹úÉöÔàѧ»á£¨ASN£©2024Äê»á½ÒÏþµÄÒ»Ïî͸ÎöÈËȺIIIÆÚʺóÆÊÎöЧ¹ûÏÔʾ£¬£¬£¬£¬ £¬Ïà±ÈrHuEPO£¬£¬£¬£¬ £¬ÅàĪɳëÄʹ¸ü¶àµÄ»¼ÕßHbˮƽά³ÖÔÚ11~13g/dL£¨57.5% vs 36.8%£¬£¬£¬£¬ £¬P=0.0002£©µÄÄ¿µÄ¹æÄ£[12]¡£¡£¡£¡£¡£¡£×ÝȻƾ֤Hbˮƽ¡Ý10g/dLÀ´Í³¼Æ´ï±êÂÊ£¬£¬£¬£¬ £¬ÅàĪɳëÄ×éÈÔÂÔ¸ßÓÚrHuEPO×飨91.8% vs 88.6%£©[13]¡£¡£¡£¡£¡£¡£
·Ç͸ÎöÈËȺÖÐÁÆЧ¸üÏÔÖø£¬£¬£¬£¬ £¬ÍíÄê¡¢Éö¹¦Ð§½Ï²îÑÇ×éÓÈΪͻ³ö
¡¶ÉöÔà¹ú¼Ê±¨¸æ¡·£¨Kidney International Reports£©½ÒÏþµÄÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å±êÇ©¡¢ÑôÐÔ±ÈÕÕ¡¢·ÇÁÓЧÐÔ¢óÆÚÁÙ´²Ñо¿£¬£¬£¬£¬ £¬¹²ÄÉÈëÀ´×Ôº£ÄÚ38ÆäÖÐÐĵÄ173Àýδ½ÓÊܹýESAsÖÎÁƵķÇ͸ÎöCKDѪÐ黼Õߣ¬£¬£¬£¬ £¬ÆÀ¹ÀÅàĪɳëıÈÕÕ¶ÌЧrHuEPOÖÎÁÆ52ÖܵÄÁÆЧºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬ £¬ÅàĪɳëÄ×éÁÆЧÆÀ¹ÀÆÚHb×Ô»ùÏßƽ¾ùÉý¸ß19.2 g/L£¬£¬£¬£¬ £¬rHuEPO×éÔòƽ¾ùÉý¸ß15.4 g/L£¬£¬£¬£¬ £¬Á½×é²î±ðΪ3.8 g/L£¨95% CI£¬£¬£¬£¬ £¬0.7¡«6.9£¬£¬£¬£¬ £¬P = 0.02£©£¬£¬£¬£¬ £¬µÖ´ïÔ¤ÉèµÄ·ÇÁÓ±ê×¼[14]¡£¡£¡£¡£¡£¡£
ÌìÏÂÉöÔಡ´ó»á£¨WCN£©2025´ó»áÉÏÐû²¼µÄÒ»ÏîÕë¶Ô·Ç͸ÎöÈËȺIIIÆÚÑо¿µÄʺóÆÊÎöÏÔʾ£¬£¬£¬£¬ £¬Ïà±ÈrHuEPO×飬£¬£¬£¬ £¬ÅàĪɳëÄ×éHbˮƽ×Ô»ùÏßÖÁÁÆЧÆÀ¹ÀÆÚ£¨16~24ÖÜ£©µÄÉý¸ß¸üΪÏÔÖø£¨1.920 vs 1.542 g/dL£¬£¬£¬£¬ £¬P=0.0163£©£¬£¬£¬£¬ £¬ÓÈÆäÔÚÍíÄê¡¢»ùÏßeGFR½ÏµÍµÈÑÇ×黼ÕßÖÐÁÆЧ¸üΪͻ³ö¡£¡£¡£¡£¡£¡£¸ÃÑо¿»¹·¢Ã÷£¬£¬£¬£¬ £¬Ïà±ÈrHuEPO£¬£¬£¬£¬ £¬ÅàĪɳëĶÔÌú´úлӰÏì½ÏС£¡£¡£¡£¡£¡£¬£¬£¬£¬ £¬¶Ô²¹ÌúµÄÐèÇó¸üµÍ[15]¡£¡£¡£¡£¡£¡£
ÐÄѪ¹Ü²»Á¼ÊÂÎñΣº¦µÍ
Õë¶Ô͸ÎöÈËȺºÍ·Ç͸ÎöÈËȺµÄIIIÆÚÑо¿Öоù·¢Ã÷£¬£¬£¬£¬ £¬ÅàĪɳëÄ×éµÄ¸´ºÏÇå¾²ÐÔÊÂÎñ£¨°üÀ¨È«ÒòéæÃü¡¢×äÖкÍÐļ¡¹£ËÀ£©ºÍÆäËûÐÄѪ¹ÜÊÂÎñ£¨°üÀ¨ÐèҪסԺÖÎÁƵIJ»Îȶ¨ÐĽÊÍ´ºÍÐèҪסԺÖÎÁƵÄÐÄÁ¦Ë¥½ß£©±¬·¢ÂÊÔÚÊýÖµÉϾùµÍÓÚrHuEPO×é[10,13]¡£¡£¡£¡£¡£¡£Õë¶Ô͸ÎöÈËȺµÄIIIÆÚÑо¿ÊºóÆÊÎö»¹ÏÔʾ£¬£¬£¬£¬ £¬ÅàĪɳëÄ×éµÄ¸ßѪѹ¡¢¸Î¶¾ÐԺ͸߼ØѪ֢±¬·¢ÂÊÔÚÊýÖµÉÏÒ²¾ùµÍÓÚrHuEPO×é[12]¡£¡£¡£¡£¡£¡£
ASN 2025½ÒÏþµÄÕë¶ÔÁ½ÏîIIIÆÚÁÙ´²Ñо¿µÄʺóÆÊÎöÏÔʾ£¬£¬£¬£¬ £¬ÔÚ͸Îö»¼ÕßÖУ¬£¬£¬£¬ £¬ÅàĪɳëÄÏà±ÈrHuEPO±ÈÕÕ×éµÄ5P-MACE£¨°üÀ¨ÐÄѪ¹ÜéæÃü¡¢Ðļ¡¹£ËÀ¡¢×äÖС¢²»ÎȹÌÐÔÐĽÊÍ´¼°ÐèסԺµÄÐÄÁ¦Ë¥½ß£©Î£º¦Ï½µ65%£¨HR 0.35£¬£¬£¬£¬ £¬95%CI 0.11-1.10£©£¬£¬£¬£¬ £¬·Ç͸Îö»¼ÕßÖÐÔòÏà±È±ÈÕÕ×éϽµ86%£¨HR 0.14£¬£¬£¬£¬ £¬95%CI 0.02-1.28£©[13]¡£¡£¡£¡£¡£¡£ÌáÐÑÅàĪɳëÄÏà±È¹Å°å¶ÌЧrHuEPO¾ßÓнµµÍÐÄѪ¹ÜÊÂÎñΣº¦µÄDZÔÚ»ñÒæ¡£¡£¡£¡£¡£¡£
Ò»Ïî»úÖÆÑо¿´Óϸ°û²ãÃæ֤ʵÁËÅàĪɳëĵÄÁ¼Ê¢ÒâѪ¹ÜÇå¾²ÐÔ¿ÉÄÜÓëÆä¶ÔEPOÊÜÌåµÄÑ¡ÔñÐÔÓйء£¡£¡£¡£¡£¡£¸ÃÑо¿·¢Ã÷ÅàĪɳëÄÄܹ»ÒÖÖÆEPOR-CD131Òì¶þ¾ÛÌåÐγɣ¬£¬£¬£¬ £¬×è¶ÏJAK2/STAT3ÐźÅͨ·µÄ¼¤»î£¬£¬£¬£¬ £¬´Ó¶ø¼õÇáÄò¶¾Ö¢¶¾ËØÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó£¬£¬£¬£¬ £¬Ê©Õ¹ÐÄÔà±£»£»£»£»£»£»£»£»¤×÷ÓÃ[16]¡£¡£¡£¡£¡£¡£
ÁÙ´²ÑÖ¤ÒÀ¾ÝÅú×¢£¬£¬£¬£¬ £¬Ê¥ÂÞÀ³?×÷ΪȫÇòΨһÉÏÊеÄС·Ö×ÓëÄÀàÉöÐÔѪÐéÖÎÁÆÒ©Î£¬£¬£¬ £¬ÎÞÂÛÔÚ͸Îö»ò·Ç͸ÎöÈËȺÖУ¬£¬£¬£¬ £¬¾ùÌåÏÖ³öÓÅÒìµÄÁÆЧÓëÓÅÒìµÄÇå¾²ÐÔ£¬£¬£¬£¬ £¬²¢Õ¹ÏÖ³öDZÔÚµÄÐÄѪ¹Ü±£»£»£»£»£»£»£»£»¤ÓÅÊÆ¡£¡£¡£¡£¡£¡£ÆäÿÔÂÒ»´Î¸øÒ©½«ÓÐÖúÌáÉý»¼ÕßÒÀ´ÓÐԺ͸ÄÉƺã¾ÃЧ¹û£¬£¬£¬£¬ £¬ÖúÁ¦»¼Õß»ñµÃ¸ü¿µ½¡¡¢¸üÓÐ×ðÑϵÄÉúÑÄ¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1. ÖйúÉöÐÔѪÐéÕïÖÎÁÙ´²Êµ¼ùÖ¸ÄÏ[J]. ÖлªÒ½Ñ§ÔÓÖ¾,2021,101(20):1463-1502.
2. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1S):S1¨CS99.
3. ÅàĪɳëÄ×¢ÉäҺ˵Ã÷Ê飨ÐÞËûÈÕÆÚ£º2024Äê04ÔÂ03ÈÕ£©
4. ¹ú¼ÒÒ©¼à¾ÖÅú×¼ÅàĪɳëÄ×¢ÉäÒºÉÏÊÐ. https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20230630195113151.html£¨Ðû²¼Ê±¼ä£º2023-06-30£©
5. ³¤Ð§ºìϸ°ûÌìÉú´Ì¼¤¼ÁÖÎÁÆÉöÐÔѪÐéÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.
6. Ö¸µ¼ÉöÐÔѪÐ黼Õß×ÔÎÒÖÎÀíµÄÖйúר¼Ò¹²Ê¶(2024°æ)[J]. ÖйúѪҺ¾»»¯,2025,24(1):1-12.
7. ÑÓ»ºÂýÐÔÉöÔಡϣÍûÁÙ´²ÖÎÀíÖ¸ÄÏ£¨2025Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2025,41(6):455-488.
8. ÖйúΧ͸ÎöÆÚÂýÐÔÉöÔಡÖÎÀíÁÙ´²Êµ¼ùÖ¸ÄÏ£¨2025Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2025,41(10):788-810.
9. Lancet Gastroenterology & Hepatology.2018(3):820
10. Ma X, Li Z, Zhang L, et al. Overview of preclinical and phase II clinical studies on Pegmolesatide's long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction. J Transl Med. 2025;23(1):144.
11. Ping Zhang, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28; 65:102273
12. Chen Jianghua,et al.Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study. ASN 2024. ABSTRACT: TH-PO888
13. Chen Jianghua, et al. Efficacy and Cardiovascular Safety of Pegmolesatide in Renal Anemia: Post Hoc Analysis of Two Phase 3 Trials. ASN 2025. Abstract: FR-PO0199
14. Xie J, Yang A, Qiu H£¬£¬£¬£¬ £¬et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney Int Rep. 2024 Dec 6;10(3):720-729.
15. Xueqing Yu,et al. Pegmolesatide for the Treatment of Anemia in Non-dialysis-dependent Chronic Kidney Disease Patients: Post-hoc Analysis of a Phase 3 Trial. WCN 2025. Abstract No: WCN25-679.
16. Zhang X, Li S, Lin T, et al. Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway. Int Immunopharmacol. 2025;167:115643.
¹ØÓÚº²ÉÖÆÒ©
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
